November 7, 2018 to November 11, 2018

Clinical Trials Session - Sunday, Nov 11 - 9:05 am
monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results
Roger Cohen - University of Pennsylvania
See the presentation

PBD-based anti-MICA/B antibody drug conjugate with a dual mechanism of action: direct tumor cell killing and restoration of NKG2D-mediated immunosurveillance
St├ęphanie Cornen, Innate Pharma
See the poster